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Administration of high-titre measles vaccine (Edmonston-Zagreb (EZ) at > 105 plaque-forming units 
(PFU) per dose) before the age of 9 months has been recommended in areas with high measles mor- 
tality before the routine age of immunization after 9 months. The study compares the long-term survival 
after high-titre measles immunization at 5 months of age with that following routine immunization with 
standard-titre vaccine at 10 months of age. At 5 months of age the high-titre group received Edmonston- 
Zagreb (EZ-HT, 5 months) or Schwarz (SW-HT, 5 months) at titres > I 0 5  PFU per dose, while the 
standard-fitre group received placebo at 5 months of age and <IO4 PFU per dose of Schwarz vaccine 
at 10 months (SW-std, 10 months). All the children were followed up to at least 36 months of age. The 
mortality ratio (MR) for infants in the EZ-HT, 5 months and SW-HT, 5 months groups was 1.32 
(P = 0.089) and 1.45 (P = 0.092), respectively, which did not differ significantly from that of recipients of 
the SW-std, 10 months. The higher MR among recipients of the high-titre vaccines was due to the sig- 
nificantly lower survival among females compared with the females who received S W-std vaccine (EZ- 
HT, 5 months M ß  = 1.76, P = 0.013; SW-HT, 5 months MR = 2.14, P = 0.017). For children aged 5-10 
months the high-titre measles vaccine did not increase mortality relative to unvaccinated children who 
had received placebo. 
Introduction 
Several studies have shown that Edmonston-Zagreb 
high-titre (EZ-HT) measles vaccine administered 
before 9 months of age is as immunogenic as 
Schwarz standard measles vaccine (SW-std) given at 
9 months of age, even with the greater levels of 
maternal antibodies that are present (1-4). In 1990 
WHO recommended that EZ-HT measles vaccine be 
used from the age of 6 months in areas where the 
incidence of and mortality from measles were high 
among under-9-month-olds to control the detrimental 
impact of measles early in life (5-11). Measles infec- 
tion before 9 months of age has a high case fatality 
rate (CFR) (11-13) and an important delayed mortal- 
ity (12, 14). 
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It had been assumed that this new policy would 
reduce overall mortality. Initial reports from Guinea- 
Bissau and Gambia supported this idea, even though 
significant reductions in mortality were not demon- 
strated (4, 6). However, a second trial in Guinea- 
Bissau, which had longer follow-up, indicated that 
girls who received EZ had significantly lower sur- 
vival rates than the female recipients of SW-std 
(15-16). We therefore carried out an assessment of 
the impact on mortality in a trial that used two high- 
titre vaccines. An interim report based on two-thirds 
of the study cohort has appeared previously (17-19). 
The present article is based on a follow-up of all 
children to at least 3 years of age. 
Subjects and methods 
Study area and popuiation 
The study was carried out in Niakhar, Senegal, a 
rural area with a population of around 26 O00 (March 
1991), which has been under demographic sur- 
veillance since 1983. Niakhar is inhabited by the 
Sereer ethnic group, who live in large compounds 
(mean size = 14.8 persons) in scattered hamlets (20). 
The population, the demographic surveillance system 
(20,21), and the epidemiology of measles in the area 
(12) have all been described in detail elsewhere. 
Briefly, during the period of the measles vaccine 
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study, the surveillance system was based on a week- 
ly visit by 12 field workers to all compounds in the 
study area in order to obtain information on births, 
deaths, marriages, migration, weaning, and any 
infections (measles and pertussis). The work of the 
field workers was monitored by two supervisors who 
contacted each assistant at least twice a week. 
High-titre measles vaccines .. 
Study design. The study was designed to investigate 
the immunogenicity, safety, and protective efficacy 
of two high-titre vaccines, particularly for children 
aged 5-10 months. All children bom to mothers resi- 
dent in the study area between 1 February 1987 and 
31 January 1989 were included in the study, pro- 
vided that they satisfied the following criteria: they 
were present at the 5-month vaccination session; 
there was no contraindication to measles vaccination; 
and their parents agreed to samples of blood being 
collected. Parents were advised to bring their chil- 
dren to one of the monthly vaccination sessions at 
the nearest health centre during the third, fifth and 
tenth month after birth. Those who did not were vis- 
ited and transport to the centre was offered to allow 
the children to be vaccinated. At 3 months of age, 
children received BCG and diphtheria-tetanus- 
pertussis/inactivated poliomyelitis (DTP/IPV), at 5 
months the second dose of DTP/IPV, and at 10 
months the third dose of DTP/IPV and yellow fever 
vaccine (Table 1). Children of resident mothers were 
randomly assigned to receive either EZ-HT, SW-HT 
or placebo (standard group) at the 5-month vaccina- 
tion session (median age, 5.1 months). The study 
was “blind” to the field workers and the mothers. 
The children in the standard group as well as those 
who had not been present at 5 months of age were 
offered the SW-std vaccine at 10 months of age 
(median age, 10.1 months). Hence, from 10 months 
of age the study was not blind since the identity of 
those children who had received a high-titre vaccine 
or a standard measles vaccine was known to the field 
workers. The weight, height, and arm-circumference 
of children who participated in the vaccination ses- 
sions at 3, 5,  and 10 months of age were measured. 
The children were also examined by a physician 
before each of the vaccinations, and given treatment 
if necessary, and chloroquine tablets for weekly 
malaria prophylaxis, normally for 2 months; their 
parents were also given nutritional advice. 
Blood samples were only collected from the 
children at 5 and 10 months of age. Analyses of the 
samples from the first group of vaccinated children 
indicated that the seroconversion rate for SW-HT 
was lower than that for EZ-HT (H. Whittle et al., 
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Table 1: Outline of the study design for administration 
of vaccines, Niakhar, Senegal, 1987-89 
Vaccines administered:a 
Age at 
(months) 5 months 5 months 10 months 
SW-std, immunization EZ-HT, SW-HT, 
3 BCG, BCG, BCG, 
DTPA PVb DTP/IPV DTPllPV 
5 EZ-UT, SW-HT, Placebo, 
DTPAPV DTPllPV DTP/IPV 
DTP/IPV DTPllPV DTP/IPV 
10 YF,c YF, SW-Std, YF, 
a EZ-HT, 5 months = Edmonton-Zagreb high-titre vaccine 
administered at 5 months of age; SW-HT, 5 months = Schwarz 
high-titre vaccine administered at 5 months of age; SW-std, 10 
months = Schwarz standard vaccine administered at 10 months 
of age. 
DTPllPV = diphtheria-tetanus-pertussis/inactivated poliomyeli- 
tis vaccine. 
YF = yellow fever vaccine. 
unpublished observations, 1988). Thus, after the first 
16 monthly cohorts, vaccination with SW-HT was 
stopped and the last eight cohorts (those bom 
between 1 June 1988 and 31 January 1989) were ran- 
domly assigned to receive either EZ-HT or placebo. 
In consequence, there were fewer children in the 
SW-HT group than in the other two groups. 
The study children who remained unvaccinated 
were offered measles vaccination in the course of 
three special campaigns during the study. After the 
study had been completed in July 1989, administra- 
tion of EZ-HT at 5-7 months of age became routine 
in the surveillance area. The use of this vaccine was 
discontinued in November 1990 and was replaced by 
SW-std administered from 9 months of age. 
Potential sources of bias. Since the trial was not 
designed to study long-term mortality, the way in 
which the study was conducted could have intro- 
duced a systematic bias in the comparison between 
recipients of high-titre vaccines and placebo/SW-std. 
Most importantly, participation at the 1 O-months 
vaccination session was higher for the standard 
group (81%) than for the EZ-HT (74%) or SW-HT 
(73%) groups, since providing measles vaccine to 
children in the placebo group was emphasized when 
those who had not appeared for vaccination were 
contacted. Only in the high-titre groups was serocon- 
version tested and the seronegative children were 
revaccinated. Furthermore, 30 unimmunized children 
in the placebo group were vaccinated with EZ-HT 
when this became the routine vaccine used in the 
area. We attempted to control for these potential 
sources of bias by both including and excluding the 
relevant groups. 
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Vaccines 
Whereas standard measles vaccines have a titre 
of <104.0 plaque-forming units (PFU), high-titre 
measles vaccine has a titre of >105.0 PFU. The 
measles vaccines used in the present study were 
kindly provided by the Institute of Immunology, 
Zagreb: and by the Institut Mérieux, Lyon.b Tests of 
potency were carried out at the MRC Laboratories in 
the Gambia. The placebo was a standard vaccine 
preparation without virus (Institut Mérieux). 
Measles surveillance 
In the study area, measles cases were found through 
the weekly visit by assistants to all compounds or 
through follow-up of the contacts of known cases. 
Compounds with suspected measles cases were vis- 
ited at least twice a week by the project physician. 
All clinical cases among children in the cohort had a 
typical rash and/or typical desquamation. 
Death ascertainment 
Most deaths among study children were identified 
through the weekly demographic surveillance sys- 
tem. Furthermore, all children in the study who still 
lived in the area were followed up individually in a 
nutritional survey in January 1992 and during the 
annual census in February 1992. At this time the 
children were aged 36-60 months. 
Information on the causes of deaths were 
obtained through verbal autopsy questionnaires (22), 
which were reviewed by two physicians who were 
blind to the vaccine group of the dead children. 
Background factors 
The following biological, cultural and socioecono- 
mic factors were examined: sex, twinning, age of 
mother, birth order, birth spacing to the preceding 
and subsequent child, age at vaccination (days), 
nutrition status at vaccination (weight, height, arm- 
circumference) (analysed using the WHO ANTHRO 
program), pre-vaccination antibody level, length of 
breast-feeding, literacy of mother, marital status of 
mother, death of mother, season (rainyjdry), measles 
infection, distance to health centre, number of house- 
holds in the compound, number of persons in the 
compound, and previous under-5-year-old mortality 
(1983-86) among children in the same compound. 
a Edmonston-Zagreb: lot 81/3; titre: 105.5 PFU (7 tests); lot 137; 
titre: 105.0 PFU (1 test). 
Schwarz high-titre: lot 09830; titre: lo5.' PFU; Schwarz stan- 
dard: titre: lo3.' PFU. 
WHO Bulletin OMS. Vol 72 1994 
Death of mother, breast-feeding, birth spacing to the 
subsequent child, measles infection, and season were 
used as time-dependent covariates. Other back- 
ground factors were assessed at birth or on the 'date 
of the 5-month session. 
Statistics 
Children were included in the survival analysis from 
the date of their vaccination at 5 months of age until 
death, migration, or follow-up in February 1992. 
Children who migrated and then retumed to the 
study area were only counted from the date of re- 
entry when they again came under surveillance for 
mortality. All children in the SW-HT group had 
reached 44 months of age, since this vaccine was 
only given at the beginning of the study, whereas chil- 
dren in the EZ-HT and standard groups were at least 
36 months of age. 
The study compares total mortality from the age 
at first vaccination (5 months). Crude death rates 
based on numbers of deaths in relation to the person- 
years-at-risk were assessed in the different vaccine 
groups. Since the difference in participation in the 
10-months vaccination session could have introduced 
a systematic bias, all estimates have been adjusted 
for participation/non-participation at this session. 
Pooled estimates were obtained using the method of 
maximum likelihood (23). Cumulative mortality risk 
at specific ages were also calculated. 
Multivariate Cox's regression analyses were car- 
ried out to control for age and the effects of back- 
ground factors (24). Age was used as the time scale 
in the Cox's regression model. Effects are expressed 
as mortality ratios (MRs). Children born in the same 
month were vaccinated in the same month. It was 
therefore not possible to distinguish the effect of sea- 
son at birth from the season at vaccination. Since 
analyses using the season-at-risk or monthly birth 
cohort gave similar results, only the season was 
used. In both the crude and the multivariate analyses, 
recipients of SW-HT were compared with children in 
the standard group from the first 16 monthly birth 
cohorts only, and the recipients of EZ-HT with all 24 
cohorts. Hence, though there was only one standard 
group, the mortality levels were not identical in the 
two comparisons between high-titre vaccine and 
standard groups (Tables 2-5; Fig. 1 and 2). 
Study approval 
The study was approved by the Ministère de la Santé 
Publique, Dakar, Senegal; by ORSTOM (Institut 
Fransais de Recherche pour le Développement en 
Coopération, Paris); and by the Ethical and Scientific 
Committees of the United Kingdom Medical Research 
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Council, Fajara, Gambia. Information meetings were 
held in the villages prior to initiating the study. 
Consent for blood sampling was obtained from the 
children’s parents at each vaccination session. 
Results 
Study children, vaccine coverage, measles infec- 
tion and vaccine efficacy. During the. study period, 
2467 children were born to mothers residing in the 
area. A total of 26 of these children were registered 
only after 5 months of age and were thus not eligible 
for the study. Before the 5-month vaccination ses- 
sion, 198 of the children had died and 66 had migra- 
ted out of the area, leaving 2177 children for inclu- 
sion in the study. Of these eligible children, 72.9% 
(1588/2177) were vaccinated at 5 months of age as 
follows: 624 received EZ-HT, 321 SW-HT, and 634 
placebo (see Tables 2-5). The 9 children who receiv- 
ed an unassigned vaccine were excluded from the 
analysis. Of the children who entered the study, 8.8% 
left the area during the follow-up period. Information 
on survival was also obtained for all 139 migrants by 
visiting their last compound of residence; seven of 
these children had died-five from the EZ-HT and 
two from the standard groups. Data for these children 
were not included in the main analysis. 
There were no differences between the three 
groups with respect to the background factors exam- 
ined (data available on request). 
In the placebo group, 78.7% (480/610) of those 
still living in the study area received SW-std at the 
10-month vaccination session. Because of subse- 
quent vaccination campaigns, coverage for measles 
vaccination increased to 86.8% in the standard group 
at 2 years of age and to 90.4% at 3 years of age. As 
described elsewhere, 20 children in the study con- 
tracted measles; five in the SW-HT, six in the EZ- 
HT, and nine in the standard group (25). Four cases 
occurred before the children had received the vac- 
cine at 5 months of age (1 in the EZ-HT and 3 in the 
standard group), a further four cases among children 
aged 5-10 months (1 in the EZ-HT and 3 in the pla- 
cebo/standard group), and 12 cases after 10 months 
of age (4 in the EZ-HT, 5 in the SW-HT, and 3 in 
placebo/standard group). Two of these children (in 
the EZ-HT and the standard group) died later. Both 
had had measles prior to being vaccinated. The effi- 
cacy (VE) of the high-titre vaccines after exposure at 
home was greater than 85% and after SW-std vacci- 
nation, 100% (25). Since there were few cases of 
measles and the case fatality was low, a large benefi- 
cial impact on survival was not to be expected. 
A total of 5 (1%) children in the EZ-HT group 
and 31 (10%) in the SW-HT group who were sero- 
764 
negative were revaccinated with either EZ-HT or 
SW-std. Furthermore, 30 unimmunized children in 
the placebo group were vaccinated with EZ-HT when 
this became the routine vaccine used in the area. 
Total mortality and mortality by sex and age 
Schwarz high-titre vaccine. Table 2 shows the 
annual mortality rates and mortality ratios by age 
and sex for the SW-HT and standard groups. The 
mortality rates for children who did or did not attend 
the vaccination session at 10 months of age were not 
significantly different (Table 3). Survival curves are 
shown in Fig. 1. The recipients of SW-HT tended to 
have higher ‘mortality than the standard group, 
though this difference was not statistically significant 
(MR = 1.45 (95% confidence interval (CI) = 0.94- 
2.23), P = 0.092). Overall, female recipients of SW- 
HT had a higher mortality rate than the standard 
group (MR = 2.14 (95% CI = 1.12-4.09), P = 0.017) 
(Table 3), although a test for interaction between sex 
and vaccine was not significant (P  = 0.095). There 
were no differences among boys. 
For SW-HT, the mortality ratio was 1.43 (95% 
CI = 0.64-3.14) for children aged 5-10 months, when 
the standard group had not yet received measles vac- 
cine. If the analysis is restricted to children who were 
present at both the 5- and 10-month vaccination 
sessions, the mortality ratio compares the high-titre 
vaccines at 5 months with the placebo at 5 months 
plus standard-titre vaccine at 10 months (MR = 1.35 
(95% CI = 0.85-2.14), P = 0.25); for females only: 
MR = 2.14 (95% CI = 1.09-4.18), P = 0.03). 
The above differences in mortality remained 
unaltered if revaccinated children were excluded 
from the SW-HT group or if children in the standard 
group who were vaccinated late with high-titre vac- 
cine or if migrants were included in the analysis. We 
assessed the effects on mortality of the biological, 
cultural, and socioeconomic background factors 
independently of vaccination group. The only factors 
significantly associated with mortality were season, 
height, weight, and the death of the mother. Adjust- 
ment for these factors as well as for age and sex in a 
Cox’s model had no effect on the mortality ratio of .  
all recipients of SW-HT compared with the standard a 
Edmonston-Zagreb high-titre vaccine. Table 4 
shows the annual mortality rates and mortality ratios 
by age and sex for the EZ-HT and standard groups. 
Mortality rates for children who did or did not attend 
the 10-month session were not significantly different 
(Table 5).  The survival curves are shown in Fig. 2. 
Recipients of EZ-HT tended to have higher mortality 
than the standard group, although this difference was 
group (MR = 1.46 (95% CI = 0.95-2.25), P = 0.087). 
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not statistically significant ( M R  = 1.32 (95% CI = 
0.96-1.82), P = 0.089). A test for interaction between 
sex and vaccine type was not statistically significant 
(P = 0.074), but females in the EZ-HT group had a 
significantly higher mortality rate than those in the 
standard group, both overall (P = 0.013) and after 10 
months of age, irrespective of whether they had 
attended the 10-month vaccination session. There 
were no differences for boys. If the analysis is 
restricted to children who were present at both the 5- 
and IO-month vaccination sessions, the mortality 
ratio compares high-titre vaccine at 5 months with 
placebo at 5 months plus standard-titre vaccine at 10 
months (MR = 1.14 (95% CI = 0.80-1-63), P = 0.48; 
for females only: MR = 1.56 (95% CI = 0.94-2.57), 
P = 0.080). 
For EZ-HT, the mortality ratio was 0.60 (95% 
CI = 0.27-1.31) between 5 and 10 months, when the 
standard group had not yet received measles vaccine. 
The corresponding values were 1.57 (1.09-2.24) 
from 10 months, when standardized for participation, 
and 2.02 (95% CI = 1.17-3.47) from 2 years of age, 
indicating an interaction with the time since vaccina- 
tion (P = 0.039). 
Control of the potential sources of bias did not 
change the mortality ratios, nor did adjustment for 
significant background factors modify the mortality 
estimate for recipients of EZ-HT compared with the 
standard group (MR = 1.33 (95% CI = 0.96-1.83), 
P = 0.083). The last three monthly cohorts did 
not receive the same lot of EZ-HT vaccine (lot 137) 
as the first 21 cohorts (lot 81/3). There was no dif- 
Sex-specific survival after high-titre measles vaccination 
Fig. 1. Survival rates, by sex, for recipients of Schwarz 
(SW) high-titre measles vaccine and standard vaccine 
(Con). Data are for children born from Februarv 1987 to 
May 1988, Niakhar, Senegal (M = males; F = females). 
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For the standard group who received SW-std at 
10 months of age, as opposed to recipients of EZ-HT 
and SW-HT at 5 months of age, females had a lower 
mortality (MR = 0.57 (95% CI = 0.31-1.06)). 
Among the unimmunized children in the standard 
group who died, there was no difference in the sex 
ratio (MR = 1.08); 10 girls and 7 boys died aged 
0.67-2.02)). 
Table 2: Number of deaths, person-years-at-risk (PYR) and annúal mortality rate, up to February 1992, according to 
sex, age, and period, for recipients of Schwarz high-titre (SW-HT) and standard measles vaccinea 
No. of deaths/PYR (annual mortality rate) Vaccination Mortality ratio 
arom Males Females Total (femaleshnales) 
5-70 months 
SW-HT 6/61.3 (0.098); n = 152 8167.3 (0.119); n = 169 14/128.6 (0.109); n = 321 1.21; 0.42-3.47b 
Standard 7/72.4 (0.097); n = 180 4n1.1 (0.056); n = 175 111143.6 (0.077); n = 355 0.58; 0.17-7.99 
Mortality ratioc 1.01; 0.34-3.07 2.1 1; 0.64-7.02 1.43; 0.64-3.14 
After 10 months 
SW-HT 14/471.4 (0.030); n = 146 19/492.4 (0.039); n = 159 33/963.8 (0.034); n = 305 1.30; 0.65-2.59 
Standard 16h31.5 (0.030); n = 172 10/556.3 (0.018); n = 171 2W1087.7 (0.024); n = 343 0.60; 0.27-1.32 
Mortality ratioC 0.99; 0.48-2.02 2.15 ; 7.00-4.62 1.43; 0.86-2.39 
Total 
SW-HT 20E32.6 (0.038); n = 152 27/559.8 (0.048); /I = 169 47/1092.3 (0.043); n = 321 1.28; 0.72428 
Standard 23/603.8 (0.038); 17 = 180 14E27.4 (0.022); n = 175 37/1231.2 (0.030); n = 355 0.59; 0.30-7.14 
Mortality ratioc 0.99; 0.54-7.81 2.14; 1.72-4.09 1.45; 0.94-2.23 
a Data apply only to the first 16 monthly birth cohorts. All children entered at 5 months and had reached at least 44 months of age; 
the mortality risk ratio at 44 months was 1.48 (95% confidence interval = 0.96-2.28); P = 0.074. 
Figures in italics are the 95% confidence intervals. 
Mortality ratio for SW-HTktandard group. 
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Table 3: Number of deaths, person-years-at-risk (PYR), and annual mortality rate from 10 months of age, up to Feb- 
ruary 1992, according to sex and presence at the 10-month vaccination session for recipients of Schwarz high-titre 
(SW-HT) and standard measles vaccinea 
No. of deaths1PYR (annual mortality rate) 
Vaccination 
group Males Females Total (femaleshales) 
Mortality ratio 
Present at 1 O-month 
vaccination ' 
SW-HT W321.6 (0.025); = 100 171377.9 (0.045); n = 124 2U699.5 (0.036); n = 224 1.80; 0.78-4.18b 
Standard 14/414.3 (0.034); n i 133 91429.7 (0.021); n = 132 23B44.0 (0.027); n = 265 0.62; 0.27-1.43 
Mortality ratioC 0.74; 0.31-1.75 2.15; 0.96-4.82 1.31; 0.74-2.31 
Not present at IO-monfh 
vaccination 
SW-HT 61149.8 (0.040); n = 46 21114.5 (0.018); n = 35 81264.3 (0.030); n = 81 0.44; 0.09-2.19 
Standard 2A17.2 (0.017); n = 39 11126.6 (0.008); n = 39 31243.7 (0.012); n = 78 0.46; 0.04-5.10 
Mortality ratioC 2.35; 0.47-1 1.62 2.21 ; 0.20-24.38 2.46; 0.65-9.27 
a Data apply only to the first 16 monthly birth cohorts. 
Figures in italics are the 95% confidence intervals. 
Mortality ratio for SW-HT1standard group. 
1 
5-10 months and 3 girls and 5 boys after 10 months 
of age. 
Causes of deaths 
Analysis of the causes of death (Table 6) indicated 
no clear difference by sex or type of vaccine. There 
were more female deaths in the high-titre groups, but 
the distribution of causes of death did not differ 
significantly. These conclusions were not changed 
when the distribution was analysed by age. 
Nutritional status 
There were no significant differences in nutritional 
status between the three groups at the 5- or 10- 
month vaccination sessions. However, boys had 
significantly lower height-for-age (H/A) than girls at 
both sessions (P< 0.05). In addition they had lower 
weight-for-age (W/A) and weight-for-height (WEI) 
at the 10-month examination (P ~0 .05) .  
In a survey conducted in November-December 
1990, when the children were 2-4 years of age, boys 
Table 4: Number of deaths, person-years-at-risk (PYR), and annual mortality rate, up to February 1992, according to 
sex, age, and period for recipients of Edmonston-Zagreb high-titre (EZ-HT) and standard measles vaccinea 
No. of deaths1PYR (annual mortality rate) 
Mortality ratio 
Males Females Total (femaleshales) 
5-10 months 
EZ-HT 4/120.4 (0.033); n = 298 6/132.6 (0.045); n = 326 101252.9 (0.040); n = 624 1.36; 0.38-4.81b 
Standard 7/127.0 (0.055); n = 313 101130.9 (0.076); n = 321 17/257.9 (0.066); n = 634 1.38; 0.53-3.62 
Mortality ratioC 0.60; O. 18-2.06 0.59; 0.22-1.63 0.60; 0.27-1.30 
After 1 O months 
EZ-HT 32/783.9 (0.041); n = 288 45B49.8 (0.053); n = 315 77/1633.7 (0.047); n = 603 1.30; 0.82-2.04 
Standard 31/818.1 (0.038); n = 301 19B63.3 (0.022); n = 31 1 5011681.4 (0.030); n = 612 0.58; 0.33-1.03 
Mortality ratioC 1.08; 0.66-7.77 2.41 ; 1.41-4.11 1.59; 1.11-2.26 
Total 
EZ-HT 36/904.3 (0.040); n = 298 51/982.4 (0.052); n = 326 8711886.6 (0.046); n = 624 1.30; 0.85-1.99 
Standard 381945.1 (0.040); n = 313 291994.2 (0.029); n = 321 67/1939.3 (0.035); n = 634 0.73; 0.45-1.18 
Mortality ratioC 0.97; 0.62-1.54 1.76; 1.12-279 1.32; 0.96-1.82 
a Data are for all 24 monthly birth cohorts. All children entered at 5 months and had reached at least 36 months of age; the mortality 
risk ratio at 36 months was 1.17 (95% confidence interval = 0.841.62); P = 0.348. 
Figures in italics are the 95% confidence intervals. 
Mortality ratio for EZ-HT/standard group. 
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Fig. 2. Survival rates, by sex, for recipients of Edmons- 
towZagreb (EZ) high-titre measles vaccine and standard 
vaccine (Con). Data are for children born from February 
1987 to January 1989, Niakhar, Senegal (M = males; 
F = females). 
, I l I I I l L _. 
6 12 18 24 30 36 42 48 54 61 
Age (months) 
still had lower W/A and H/A values than girls 
(P ~ 0 . 0 5  in each case). There were significantly 
more girls in the EZ-HT than in the standard group 
who had z-scores of -3 or lower for W/A (14/249 
versus 61269); P = 0.045) and HIA (34/251 versus 
21/269); P = 0.033).' 
Data available on request. 
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Discussion 
Although OUT results suggest that survival may be 
lower following administration of EZ and SW high- 
titre measles vaccines at 5 months of age than that 
associated with administration of standard Schwarz 
measles vaccine at 9-10 months of age, the dif- 
ferences were not statistically' significant. At 36 
months, an age reached by all the children, the mor- 
tality risk ratio was only 1.17 for the EZ-HT group 
(0.91 for boys and 1.44 for girls). Hence, OUT obser- 
vations contrast with a preliminary communication 
of this data, which reported a risk ratio of 1.80 (at 41 
months of age) and no sex difference (17). As noted 
previously (18), for children enrolled during the last 
third of the study there was no increased mortality 
among those who received the high-titre EZ vaccine. 
The major cause for concern is therefore the possible 
interactions between high-titre vaccines and sex and 
the time since vaccination. Female recipients of both 
EZ-HT and SW-HT vaccines had significantly lower 
survival than females in the standard group; how- 
ever, this occurred only after 10 months of age, when 
most children in the comparison group had received 
SW-std vaccine. Thus, the present study reproduced 
patterns seen in Bissau (15,16). 
The present study was not designed to examine 
a difference in morbidity or mortality beyond 10 
months of age and bias could have been introduced 
as discussed below. First, participation at the 10- 
month vaccination session was higher in the standard 
group. Since the children were examined clinically at 
Table 5: Number of deaths, person-years-at-risk (PYR), and annual mortality rate from 10 months of age, up to Feb- 
ruary 1992, according to sex, age, and presence at the 10-month vaccination session for recipients of Edmonston- 
Zagreb high-titre (EZ-HT) and standard measles vaccinea 
No. of deaths/PYR (annual mortality rate) Mortality ratio 
Males Females Total (femaleslmales) 
Present at 10-month 
vaccina fion 
EZ-HT 2W579.9 (0.035); n = 213 31/615.6 (0.050); n = 230 51/1195.5 (0.043); n = 443 1.46; 0.83-2.5@ 
Standard 27/675.6 (0.040); n = 248 16/698.4 (0.023); n = 248 43/.1374.0 (0.031); n = 496 0.57; 0.31-1.06 
Mortality ratioC 0.86; 0.48-1.54 2.20; 1.20-4.02 136; 0.91-2.05 
Not present at IO-month 
vaccination 
EZ-HT 12/204.0 (0.059); n = 75 14/234.2 (0.060); n = 85 26/438.2 (0.059); n = 160 1.02; 0.47-2.19 
Standard 4/142.5 (0.028); n = 53 3A64.9 (0.018); n = 63 7/307.4 (0.023); n = 116 0.65; 0.15-2.89 
Mortality ratioC 2.10; 0.68-6.50 3.29; 0.94-1 1.44 2.61 1.13-6.00 
a Data are for all 24 monthly birth cohorts. 
Figures in italics are the 95% confidence interval. 
Mortality ratio for EZ-HTktandard group. 
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Table 6: Causes of death, according to sex and vaccine group, Niakhar, Senegal, 1987-92 
Cause of 
death EZ-HT SW-HT Standard EZ-HT SW-HT Standard 
No. of deaths among girlsa No. of deaths among boysa 
Diarrhoea 11 (22)b 5 (19) 7 (24) 15 (42) 5 (25) 9 (24) 
Malnutrition . 14 (27) 5 (19) 6 (21) 7 (19) 4 (20) 5 (13) 
Pneumonia 3 (6) 
Other specific 5 (10) . 3 (11) 
Malaria 11 (23) 5 (19) 6 (21) 5 (14) 2 (10) 10 (26) 
5 (19) 2 (7) 1 (3) 3 (15) 2 (5) 
0 (0) 2 (6) 1 (5) 1 (3) 
c 
Unknown 7 (14) 4 (15) 8 (28) 6 (17) 5 (25) 11 (29) 
Total 51 (100) 27 (100) 29 (100) 36 (1 00) 20 (100) 38 (100) 
a EZ-HT = Edmonston-Zagreb high-titre; SW-HT = Schwarz high-titre. 
Figures in parentheses are percentages. 
all vaccination sessions, the medication they re- 
ceived could have affected their survival. However, 
the mortality ratios were unaffected when adjusted 
for participation. For girls, mortality was higher both 
among participants and those who did not attend the 
10-month vaccination session. Second, seronegative 
children in the two high-titre groups were revaccina- 
ted with another measles vaccine. Exclusion of the 
revaccinated children did not affect the mortality 
estimates. Third, some children in the standard group 
were vaccinated with EZ-HT .when this became the 
routine vaccine used in the study area. Censoring at 
the time of vaccination eliminated a group of non- 
attenders from the standard group. However, inclu- 
sion of these children in the standard group would 
not have affected the mortality ratios. 
Special efforts were made to trace all the study 
children. Hence, there was no loss to follow-up that 
altered the observed tendencies. We were unable to 
identify any other methodological or randomization 
problem to indicate that our conclusions are biased. 
One of the reasons for the sex-specific differ- 
ences that we have reported was the low mortality 
among girls in the standard group (Tables 2 and 4). 
Although unexpected, this lower mortality (MR 
(F/M) = 0.57) reflects that found in the preceding 
and succeeding 2-year periods (MR = 0.63 and 0.73, 
resp.) (26). 
Since significantly lower female survival has not 
been observed in trials using medium-titre E2 vac- 
cine (< 50000 PFU) (4,  6),  the dose of vaccine 
might be important in determining long-term mortal- 
ity, which increased after intensive exposure to the 
wild virus (11, 12, 14). If high-titre or standard mea- 
sles vaccines affect females differently, the reasons 
for this are not clear. A low efficacy of high-titre 
vaccines for girls could have led to lower survival; 
however, the incidence of measles was low and the 
vaccine efficacy was good (25). There was no indi- 
cation that boys received better care, which could 
influence the relative mortality for girls if high-titre 
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vaccines were likely to increase the morbidity of all 
children. The length of breast-feeding was the same 
for boys and girls. Infection with human immunodef- 
iciency virus (HIV), which could interact with a 
hi h-titre measles vaccine, is uncommon in the study 
&ea (17). A number of host characteristics are cur- 
rently under investigations, including antibody levels 
and state of nutrition at the time of vaccination. 
Although sex-specific differences have been 
observed in antibody levels and state of nutrition, 
these are unlikely to explain fully the mortality pat- 
tern after high-titre immunization. 
In Niakhar, the reduced survival of girls in the 
high-titre group was observed only after children in 
the comparison group had received SW-std (Tables 
2-5). Also, EZ vaccine has not been associated with 
increased mortality in areas with low mortality (4, 
27). Since SW-std measles vaccine reduces mortality 
more than can be accounted for by simply preventing 
acute measles infection (10, I I ) ,  this vaccine may 
produce beneficial effects that are not generated by 
the high-titre vaccines. 
No estimates have appeared of the expected 
increase in survival brought about by switching from 
SW-std vaccine at 9 months to EZ-HT at 6 months in 
areas where the incidence and mortality from mea- 
sles are high before 9 months of age (5). However, 
such benefits are unlikely to outweigh the 20% high- 
er mortality in high-titre recipients found in both 
Bissau (15, 16) and Niakhar. Since there is no obvi- 
ous explanation for the delayed mortality or for the 
sex-specific effects of measles vaccine, concern has 
been raised about the general validity of our observa- 
tions (13, which have not been noted in other areas 
where the general mortality is lower than in Senegal 
and Guinea-Bissau (4, 27). However, the sex-specif- 
ic tendency has been reported in several studies (16, 
28, and P. Aaby unpublished data, 1992). Further 
research to define the biological basis of these epi- 
demiological findings is therefore needed. In view of 
the consistency of the results in three study areas, the 
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EPI Global Advisory Group has recently recom- 
mended that high-titre measles vaccines should no 
longer be used in routine immunization programmes 
(28). 
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Résumé 
Différences de mortalité liées au sexe 
après administration de vaccin 
antirougeoleux à titre élevé dans des 
régions rurales du Sénégal 
L‘administration d’un vaccin antirougeoleux a titre 
élevé (Edmonston-Zagreb (EZ) à >IO5 unités for- 
matrices de plage (UFP) par dose) avant I’âge de 
9 mois a été recommandée dans les régions oÙ la 
mortalité rougeoleuse est forte chez les enfants 
n’ayant pas encore atteint I’âge normal de la vac- 
cination. Dans la présente étude, réalisée dans 
des régions rurales du Sénégal, nous avons com- 
paré la survie à long terme après vaccination à 5 
mois avec un vaccin antirougeoleux à titre élevé 
et après vaccination selon le schéma habituel a 
I’âge de 10 mois avec un vaccin à titre standard. 
Les enfants du groupe “titre élevé” ont reçu a 
I’âge de 5 mois le vaccin Edmonston-Zagreb (EZ- 
H i )  ou Schwarz (SW-HT) à un titre > I O 5  UFP par 
dose, tandis que ceux du groupe “titre standard” 
ont reçu un placebo à I’âge de 5 mois et une 
dose <IO4 UFP de vaccin Schwarz à I’âge de 10 
mois (SW-std). Tous les enfants ont été suivis au 
moins jusqu’à I’âge de 36 mois. Le taux de morta- 
lité (MR) chez les enfants ayant reçu le EZ-HT OU 
le SW-HT à 5 mois était, respectivement, de 1,32 
(intervalle de confiance (CI) à 95%: 0,96-1,82) 
(P = 0,089) et 1,45 (CI 95%: 0,94-2,23) (P  = 0,092), 
et ne différait pas significativement du taux obser- 
vé chez les enfants ayant reçu le SW-std à 10 
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mois. La tendance a une mortalité plus forte chez 
les enfants ayant reçu le vaccin à titre élevé résul- 
tait du taux significativement plus faible de survie 
chez les filles de ce groupe par rapport aux filles 
ayant reçu le vaccin standard (EZ-HT: MR = 1,76 
2,14 (CI 95% = 1,124,09), P = 0,017). Par rap- 
port aux garçons, cette différence était due non 
seulement au plus faible taux de survie dans les 
groupes SW-HT et EZ-HT mais aussi à une aug- 
mentation inattendue de la survie dans le groupe 
SW-std. Chez les garçons, on n’observait pas de 
différence significative de mortalité. De plus, chez 
les enfants âgés de 5 à 10 mois, le vaccin a titre 
élevé augmentait la mortalité par rapport aux 
enfants non vaccinés ayant reçu un placebo. Ces 
données, jointes à celles d’autres études, ont 
conduit le groupe consultatif mondial du PEV à 
recommander l’arrêt de l’emploi des vaccins à titre 
élevé dans les programmes de vaccination. 
(CI 95% = 1 ,I 2-2,79), P = 0,013; SW-HT: MR = 
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